Novo Nordisk and Eli Lilly rival soars 26% after promising test results
February 26, 2024 at 05:30 AM EST
Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.
Photography by Christophe Tomatis